260 related articles for article (PubMed ID: 16298292)
1. Resurrection men dig through the drug graveyard: ARYx revives problem blockbuster drugs.
Wolfson W
Chem Biol; 2005 Nov; 12(11):1155-6. PubMed ID: 16298292
[No Abstract] [Full Text] [Related]
2. Surviving the blockbuster syndrome.
Service RF
Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
[No Abstract] [Full Text] [Related]
3. Big interest in heavy drugs.
Sanderson K
Nature; 2009 Mar; 458(7236):269. PubMed ID: 19295573
[No Abstract] [Full Text] [Related]
4. Redesigner drugs.
Dove A
Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
[TBL] [Abstract][Full Text] [Related]
5. Strength and honor through the pharmaceutical industry's embrace of green chemistry?
Fortunak J; Confalone PN; Grosso JA
Curr Opin Drug Discov Devel; 2007 Nov; 10(6):651-3. PubMed ID: 17987518
[No Abstract] [Full Text] [Related]
6. How much do clinical trials cost?
Martin L; Hutchens M; Hawkins C; Radnov A
Nat Rev Drug Discov; 2017 Jun; 16(6):381-382. PubMed ID: 28529317
[No Abstract] [Full Text] [Related]
7. In biomarkers we trust?
Baker M
Nat Biotechnol; 2005 Mar; 23(3):297-304. PubMed ID: 15765081
[No Abstract] [Full Text] [Related]
8. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
9. IP litigation in China could drive innovation.
Jia H
Nat Biotechnol; 2004 Apr; 22(4):368. PubMed ID: 15060539
[No Abstract] [Full Text] [Related]
10. Macro trends in pharmaceutical innovation.
Cohen FJ
Nat Rev Drug Discov; 2005 Jan; 4(1):78-84. PubMed ID: 15688075
[TBL] [Abstract][Full Text] [Related]
11. Forging synergies in drug discovery.
Nat Chem Biol; 2008 Feb; 4(2):83. PubMed ID: 18202672
[No Abstract] [Full Text] [Related]
12. The long and winding road.
Nat Rev Drug Discov; 2005 Jun; 4(6):443. PubMed ID: 15959946
[No Abstract] [Full Text] [Related]
13. Drug target validation: Hitting the target.
Smith C
Nature; 2003 Mar; 422(6929):341, 343, 345 passim. PubMed ID: 12646927
[No Abstract] [Full Text] [Related]
14. Pharmacogenetics and drug metabolism.
Ball S; Borman N
Nat Biotechnol; 1997 Oct; 15(10):925-6. PubMed ID: 9335033
[No Abstract] [Full Text] [Related]
15. Cutting the cost of drug development?
Rawlins MD
Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
[No Abstract] [Full Text] [Related]
16. Chiral drugs viable, despite failure.
Dorey E
Nat Biotechnol; 2000 Dec; 18(12):1239-40. PubMed ID: 11101795
[No Abstract] [Full Text] [Related]
17. The pharmaceutical industry--to whom is it accountable?
Hayes TA
N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183881
[No Abstract] [Full Text] [Related]
18. Drug discovery beyond the 'rule-of-five'.
Zhang MQ; Wilkinson B
Curr Opin Biotechnol; 2007 Dec; 18(6):478-88. PubMed ID: 18035532
[TBL] [Abstract][Full Text] [Related]
19. Trading on traditional medicines.
Basu P
Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941
[No Abstract] [Full Text] [Related]
20. An integrated, multidisciplinary approach for drug safety assessment.
Li AP
Drug Discov Today; 2004 Aug; 9(16):687-93. PubMed ID: 15341779
[No Abstract] [Full Text] [Related]
[Next] [New Search]
